Viking Therapeutics Inc (VKTX NASDAQ) stock market data APIs
$22.9787
0.69(3%)
as of September 17, 2025
Try our APIs with
free plan!
Viking Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Prev. Close
22.9787
Open
23.6687
High
24.2054
Low
22.8012
52 wk Range
18.92-81.7295
Market Cap
2 664 M
Shares Outstanding
112 M
EPS
-0.58
Beta
0.722
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Viking Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
DHYAF.US
IShares II Public Limited Company - IShares High Yield Corporate Bond ESG UCITS ETF
0.28
(4.59%)
0.05
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viking Therapeutics Inc data using free add-ons & libraries
Get Viking Therapeutics Inc Fundamental Data
Viking Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-23
- EPS/Forecast: -0.44
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viking Therapeutics Inc News
New
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside lifestyl...
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on Value investing subreddit by Remarkable-Ad5326. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc...
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Though Amgen AMGN and Viking Therapeutics VKTX do not currently market any obesity drugs, they are among the few biotechs that have shown immense potential in this space. Amgen boasts a strong presen...
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Novo Nordisk NVO has secured European approval to update the label of oral GLP-1 drug for type II diabetes (T2D), Rybelsus (oral semaglutide), to reflect cardiovascular benefits demonstrated in the ph...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
